Literature DB >> 32572876

Hsa_circRNA_101036 acts as tumor-suppressor in oral squamous cell carcinoma cells via inducing endoplasmic reticulum stress.

W Deng1, J Fu, T Wang, J-X Chen, L-B Fu, W Peng.   

Abstract

OBJECTIVE: Endoplasmic reticulum (ER) stress has an effect on cancer cell proliferation and survival. TMTC1 has been reported to be involved in cell proliferation and inflammation, and development of ER. Hsa_circRNA_101036 is an exon circRNA formed by splicing of TMTC1 mRNA precursor. This study intends to explore the effect of hsa_circRNA_101036 on the malignant behavior of oral squamous cell carcinoma through endoplasmic reticulum stress.
MATERIALS AND METHODS: We firstly evaluated the levels of Hsa_circRNA_101036 in human oral mucous fibroblasts (hOMF), and in several OSCC cell lines, including FaDu, OECM1, SAS, HSC3. Then, we studied the effects of overexpression of Hsa_circRNA_101036 on the cell proliferation, apoptosis, invasion, migration, and cytokine release in OSCC cells. Finally, we evaluated the levels of CHOP that are critical in ER and the ROS levels in OSCC cells.
RESULTS: We found that compared with hOMF, a significantly lower mRNA expression of Hsa_circRNA_101036 was found in OECM1 and HSC3 cells. In OECM1 and HSC3 cells, with overexpression of Hsa_circRNA_101036, a significant decrease in cell proliferation, apoptosis, invasion, migration, and cytokine release was found. A significantly increased ROS, as well as increased protein level of CHOP, P38 and Bcl-2, was found in cells with Hsa_circRNA_101036 overexpression.
CONCLUSIONS: This study indicated that Hsa_circRNA_101036 may acts as a tumor suppressor in OSCC via regulating the ER in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32572876     DOI: 10.26355/eurrev_202006_21506

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  CircSND1/miR-182-5p Axis Promotes Proliferative and Invasive Abilities of Thyroid Cancer via Binding Targeting MET.

Authors:  Dongliang Wang; Shuilong Zhang; Dewei Li; Qiang Wang; Zhifu Xiao; Yuhang Zhang
Journal:  J Oncol       Date:  2022-05-30       Impact factor: 4.501

Review 2.  Interplay between endoplasmic reticulum stress and non-coding RNAs in cancer.

Authors:  Tianming Zhao; Juan Du; Hui Zeng
Journal:  J Hematol Oncol       Date:  2020-12-02       Impact factor: 17.388

Review 3.  The ER Stress/UPR Axis in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis.

Authors:  Mahmoud Aghaei; Sanaz Dastghaib; Sajjad Aftabi; Mohamad-Reza Aghanoori; Javad Alizadeh; Pooneh Mokarram; Parvaneh Mehrbod; Milad Ashrafizadeh; Ali Zarrabi; Kielan Darcy McAlinden; Mathew Suji Eapen; Sukhwinder Singh Sohal; Pawan Sharma; Amir A Zeki; Saeid Ghavami
Journal:  Life (Basel)       Date:  2020-12-22

4.  Circ-KIAA0907 inhibits the progression of oral squamous cell carcinoma by regulating the miR-96-5p/UNC13C axis.

Authors:  Wenjie Dong; Lei Zhao; Shiyang Zhang; Shijie Zhang; Hongyun Si
Journal:  World J Surg Oncol       Date:  2021-03-14       Impact factor: 2.754

Review 5.  The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role.

Authors:  Jing Zuo; Zhe Zhang; Maomao Li; Yun Yang; Bohao Zheng; Ping Wang; Canhua Huang; Shengtao Zhou
Journal:  Mol Cancer       Date:  2022-01-26       Impact factor: 27.401

6.  Hsa_circ_0056686, derived from cancer-associated fibroblasts, promotes cell proliferation and suppresses apoptosis in uterine leiomyoma through inhibiting endoplasmic reticulum stress.

Authors:  Meifang Suo; Zhichen Lin; Dongfang Guo; Airong Zhang
Journal:  PLoS One       Date:  2022-04-07       Impact factor: 3.240

7.  Construction of mRNA prognosis signature associated with differentially expressed genes in early stage of stomach adenocarcinomas based on TCGA and GEO datasets.

Authors:  Fuquan Jiang; Haiguan Lin; Hongfeng Yan; Xiaomin Sun; Jianwu Yang; Manku Dong
Journal:  Eur J Med Res       Date:  2022-10-17       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.